布地奈德联合噻托溴铵对慢性阻塞性肺疾病急性期疗效评价  

The treatment of chronic obstructive pulmonary disease in the acute stage of chronic obstructive pulmonary disease was evaluated by budesonide

作　　者：卞大晨 高慧 顾艺难[1] 秦少云 BIAN Da-chen;GAO Hui;GU Yi-nan;QIN Shao-yun(Jiangsu taizhou people's hospital respiratory department,jiangsu taizhou 225300,China)

机构地区：[1]江苏省泰州市人民医院呼吸科,江苏泰州225300

出　　处：《临床医药文献电子杂志》2017年第71期13863-13864,共2页Electronic Journal of Clinical Medical Literature

摘　　要：目的探讨布地奈德联合噻托溴铵治疗慢性阻塞性肺疾病急性期的疗效。方法选取我院2016年6月~2017年6月收治的COPD急性发作患者100例随机分为研究组(50例)和对照组(50例)。对照组采用布地奈德治疗;研究组采用布地奈德联合噻托溴铵治疗,对比两组7天后肺功能与临床疗效。结果研究组FEV1%值及FEV1/FVC(%)值均高于对照组,差异有统计学意义(P<0.05)。研究组总有效率、临床控制率与对照组比较,差异有统计学意义(P<0.05)。结论布地奈德联合噻托溴铵治疗有助于提高慢性阻塞性肺疾病急性期的临床疗效。Objective To evaluate the efficacy of budesonide combined with tiotropium in the treatment of chronic obstructive pulmonary disease.Methods 1A total of 100 patients(50 cases)and the control group(50 cases)were randomly divided into the study group(50 cases)and the control group(50 cases)in the patients with COPD acute attack from June 2016 to June 2017.The control group was treated with budesonide.The study group was treated with budesonide combined with tiotropium,and the lung function and clinical effect were compared after 7 days.Results FEV1%and FEV1/FVC(%)were higher in the study group than in the control group,the difference was statistically significant.The difference was statistically significant(P<0.05).the clinical control rate compared with the control group,The difference was statistically significant(P<0.05).Conclusion Combination of budesonide and tiotropium can improve the clinical efficacy of chronic obstructive pulmonary disease.

关 键 词：慢性阻塞性肺疾病 布地奈德 噻托溴铵 疗效评价 

分 类 号：R563[医药卫生—呼吸系统]